文献速递生殖医学

靶向精子活力的非激素类男性避孕研究进展

Advances in non-hormonal male contraception targeting sperm motility.
PubMed 文献 · Hum Reprod Update · 2023-01-01

本综述聚焦精子特异性靶点(酶、离子通道、跨膜转运蛋白、表面蛋白)在精子活力中的关键作用,并评估其作为非激素类男性避孕药开发靶点的可行性。尽管临床前研究已鉴定出具有抑精活性的小分子配体,但目前尚无药物进入临床开发阶段。

要点

  • 精子特异性靶点包括酶(PP1γ2、GAPDHS、sAC)、离子通道(CatSper、KSper)、转运蛋白(sNHE、SLC26A8、ATP1A4)和表面蛋白(EPPIN)。
  • 这些靶点通常位于精子鞭毛,其基因或免疫学方法在动物模型及人类基因突变中证实对精子活力和男性生育力不可或缺。
  • 临床前试验已鉴定出具有抑精活性的小分子配体,但尚无药物进入临床开发阶段。

核心结论

  • 多种精子相关蛋白作为精子活力的关键调节因子,为男性避孕提供了有吸引力的可成药候选靶点。
  • 然而,尚无药物制剂进入临床开发阶段。

研究设计与样本

  • 文献综述,检索PubMed数据库,使用关键词「spermatozoa」、「sperm motility」、「male contraception」和「drug targets」并结合相关术语,纳入截至2023年1月发表的英文文献。

主要发现

  • 鉴定出精子特异性表达或富集的候选靶点,包括酶(PP1γ2、GAPDHS、sAC)、离子通道(CatSper、KSper)、跨膜转运蛋白(sNHE、SLC26A8、ATP1A4)和表面蛋白(EPPIN)。
  • 这些靶点通常位于精子鞭毛,通过动物模型遗传或免疫学方法及人类精子缺陷相关基因突变证实其在精子活力和男性生育力中的不可或缺作用。
  • 临床前试验中鉴定出具有抑精活性的类药小分子有机配体,证明了其可成药性。

关键数值与推荐

  • 精子特异性靶点包括酶PP1γ2、GAPDHS、sAC,离子通道CatSper、KSper,跨膜转运蛋白sNHE、SLC26A8、ATP1A4,以及表面蛋白EPPIN。
  • 这些靶点通常位于精子鞭毛,其 indispensable 作用经动物模型遗传或免疫学方法及人类基因突变证实。
  • 类药小分子有机配体在临床前试验中显示抑精活性。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 尚无药物制剂达到临床开发阶段。
  • 将临床前和药物发现成果转化为适合临床开发的类药候选物的进展缓慢。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: The high rates of unintended pregnancy and the ever-growing world population impose health, economic, social, and environmental threats to countries. Expanding contraceptive options, including male methods, are urgently needed to tackle these global challenges. Male contraception is limited to condoms and vasectomy, which are unsuitable for many couples. Thus, novel male contraceptive methods may reduce unintended pregnancies, meet the contraceptive needs of couples, and foster gender equality in carrying the contraceptive burden. In this regard, the spermatozoon emerges as a source of druggable targets for on-demand, non-hormonal male contraception based on disrupting sperm motility or fertilization. OBJECTIVE AND RATIONALE: A better understanding of the molecules governing sperm motility can lead to innovative approaches toward safe and effective male contraceptives. This review discusses cutting-edge knowledge on sperm-specific targets for male contraception, focusing on those with crucial roles in sperm motility. We also highlight challenges and opportunities in male contraceptive drug development targeting spermatozoa. SEARCH METHODS: We conducted a literature search in the PubMed database using the following keywords: 'spermatozoa', 'sperm motility', 'male contraception', and 'drug targets' in combination with other related terms to the field. Publications until January 2023 written in English were considered. OUTCOMES: Efforts for developing non-hormonal strategies for male contraception resulted in the identification of candidates specifically expressed or enriched in spermatozoa, including enzymes (PP1γ2, GAPDHS, and sAC), ion channels (CatSper and KSper), transmembrane transporters (sNHE, SLC26A8, and ATP1A4), and surface proteins (EPPIN). These targets are usually located in the sperm flagellum. Their indispensable roles in sperm motility and male fertility were confirmed by genetic or immunological approaches using animal models and gene mutations associated with male infertility due to sperm defects in humans. Their druggability was demonstrated by the identification of drug-like small organic ligands displaying spermiostatic activity in preclinical trials. WIDER IMPLICATIONS: A wide range of sperm-associated proteins has arisen as key regulators of sperm motility, providing compelling druggable candidates for male contraception. Nevertheless, no pharmacological agent has reached clinical developmental stages. One reason is the slow progress in translating the preclinical and drug discovery findings into a drug-like candidate adequate for clinical development. Thus, intense collaboration among academia, private sectors, governments, and regulatory agencies will be crucial to combine expertise for the development of male contraceptives targeting sperm function by (i) improving target structural characterization and the design of highly selective ligands, (ii) conducting long-term preclinical safety, efficacy, and reversibility evaluation, and (iii) establishing rigorous guidelines and endpoints for clinical trials and regulatory evaluation, thus allowing their testing in humans.

来源:Hum Reprod Update,查看原文。版权归原作者所有。

引用

  1. Mariani NAP, Silva JV, Fardilha M, et al. Advances in non-hormonal male contraception targeting sperm motility. Hum Reprod Update. 2023. PMID: 37141450. doi:10.1093/humupd/dmad008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。